BioTelemetry, Inc. (NASDAQ:BEAT) Stock Closed -8.3% Below Its 50 Day Average


The stock is trading at $30.60 which is marginally under $33.36, the 50 day moving average and a tad below the 200 day moving average of $32.36. The 50 day moving average moved down $-2.76 and the 200 day average went down $-1.76 or -5.43%. BioTelemetry, Inc. shares had a trading volume of 295K on Tuesday. Trading volume was down 33.00% under the stocks average daily volume.

Investors are feeling more bearish on shares of the company of late looking at the motion in short interest. The stock realized a rise in short interest of 0.64% between September 15, 2017 and September 29, 2017. Short shares grew from 1,684,877 to 1,695,724 over that period. The short-interest ratio decreased to 2.0 and the percentage of shorted shares is 0.06% as of September 29.

Here are a few substantial investment firms who have updated their positions. As of quarter end Meeder Asset Management Inc had disposed of 1,323 shares trimming its holdings by 93.1%. The value of the investment in BioTelemetry, Inc. decreased from $48,000 to $3,000 a change of $45,000 quarter over quarter. Bank Of Montreal /can/ trimmed its stake by selling 1,789 shares a decrease of 35.5%. Bank Of Montreal /can/ controls 3,246 shares valued at $107,000. The total value of its holdings decreased 36.3%.

As of the end of the quarter Central Trust Co had sold a total of 1,280 shares trimming its position 92.8%. The value of the investment in (BEAT) went from $40,000 to $3,000 a change of 92.5% since the last quarter. As of the end of the quarter Summit Creek Advisors LLC had sold a total of 2,525 shares trimming its stake by 0.7%. The value of the investment in BEAT went from $11,447,000 to $11,210,000 decreasing 2.1% quarter to quarter.

The company currently has a P/E ratio of 20.54 and the market cap is 990.22M. In the latest earnings report the EPS was $1.49 and is expected to be $0.99 for the current year with 32,360,000 shares presently outstanding. Next quarter’s EPS is expected be $0.30 with next year’s EPS projected to be $1.33.

BioTelemetry, Inc., launched on April 12, 2013, provides monitoring services and digital population health management in a healthcare setting, medical device manufacturing and centralized laboratory services for clinical research. The Company operates through three segments: Healthcare, Technology and Research..